The earnings call highlighted strong revenue and earnings growth, with successful product launches and an upgraded revenue outlook. However, challenges in China, SCIT sales decline, and supply constraints in Japan were noted as areas of concern.

Company Guidance

In the call, ALK provided a detailed guidance for its fiscal year 2025. During the second quarter, the company exceeded expectations with a 12% revenue growth, driven by strong sales of adrenaline auto-injectors and the ACARIZAX tablet in Europe. Earnings in Q2 improved by 41% to DKK 375 million, resulting in an EBIT margin of 25%. ALK upgraded its full-year revenue growth outlook to 12% to 14%, maintaining the EBIT margin as it plans to invest further in growth initiatives. The company reported a 13% growth in its main sales region, with tablet sales in Europe rising by 17%. North American revenue increased by 17%, with tablet growth at 32%. Despite challenges in international markets, notably a 20% decline in SCIT revenue in China, tablet revenue grew by 9%. ALK's full-year outlook is optimistic, anticipating continued sales momentum despite global uncertainties.

Strong Revenue Growth

Q2 revenue growth exceeded expectations at over 12%, driven by adrenaline auto-injectors and improved momentum for the ACARIZAX tablet in Europe.

Earnings Improvement

Q2 earnings improved by 41% in local currencies to DKK 375 million, yielding an EBIT margin of 25%.

Sales Growth in Key Regions

Revenue in North America increased by 17%, and tablet sales in Europe increased by 17% on broad-based growth.

Successful Product Launches

Launched the neffy Adrenalin spray in Germany and entered a co-promotion deal in the U.S. with ARS Pharma.

Upgraded Full Year Revenue Outlook

The full-year revenue growth expectation was upgraded to 12% to 14%.

ALK-abello (AKBLF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AKBLF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	- / -	0.157	―	―	―
Aug 21, 2025	2025 (Q2)	0.20 / 0.19	0.141	33.33% (+0.05)
May 06, 2025	2025 (Q1)	0.21 / 0.25	0.172	45.45% (+0.08)
Feb 19, 2025	2024 (Q4)	0.15 / 0.13	0.104	20.30% (+0.02)
Nov 14, 2024	2024 (Q3)	0.12 / 0.16	0.078	100.00% (+0.08)
Aug 22, 2024	2024 (Q2)	0.11 / 0.14	0.047	200.00% (+0.09)
May 02, 2024	2024 (Q1)	0.15 / 0.17	0.115	49.66% (+0.06)
Feb 08, 2024	2023 (Q4)	0.12 / 0.10	0.047	121.67% (+0.06)
Nov 15, 2023	2023 (Q3)	0.06 / 0.08	0.019	306.50% (+0.06)
Aug 24, 2023	2023 (Q2)	0.04 / 0.05	0.025	87.50% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AKBLF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 21, 2025	$29.48	$30.55	+3.63%
May 06, 2025	$24.02	$25.30	+5.33%
Feb 19, 2025	$21.66	$22.82	+5.36%
Nov 14, 2024	$22.88	$22.60	-1.22%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ALK-abello A/S Class B (AKBLF) report earnings?

ALK-abello A/S Class B (AKBLF) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is ALK-abello A/S Class B (AKBLF) earnings time?

ALK-abello A/S Class B (AKBLF) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AKBLF EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing